Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Evolving into a phase II company
Press releases
-
Positive data from the clinical phase I MAD study with AlzeCure’s Alzheimer’s project NeuroRestore ACD856
June 29, 2022
-
First patient included in AlzeCure’s Phase II clinical trial in neuropathic pain with non-opioid ACD440
June 21, 2022
-
Study plan of AlzeCure’s Phase II clinical study in neuropathic pain with non-opioid ACD440 now available
June 15, 2022
Financial reports
-
AlzeCure publishes its interim report for January – March 2022
May 5, 2022
-
AlzeCure Pharma publishes its Annual Report for 2021
April 6, 2022
-
AlzeCure publishes its Year-end report for 2021
February 24, 2022